Jin Zeng

Title: The Innovative Contributions of Jin Zeng

Introduction

Jin Zeng is a notable inventor based in Audubon, PA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate KRAS mutations. With a total of 2 patents to his name, Zeng's work is paving the way for advancements in cancer treatment.

Latest Patents

Zeng's latest patents include innovative compounds aimed at modulating KRAS G12D and other G12 mutants. The first patent, titled "KRAS modulators and uses thereof," provides a range of KRAS modulating compounds, including various formulas and their pharmaceutically acceptable derivatives. The second patent, "Pyrimidine based modulators and uses thereof," focuses on compounds that are also effective in modulating KRAS GD12 and other G12 mutants. These patents highlight Zeng's commitment to addressing critical challenges in cancer therapy.

Career Highlights

Jin Zeng is currently associated with Quanta Therapeutics, Inc., where he continues to innovate in the field of drug development. His work is characterized by a strong focus on creating effective treatments for patients with specific genetic mutations. Zeng's expertise and dedication have positioned him as a key figure in his field.

Collaborations

Zeng collaborates with talented professionals such as Hong Lin and Juan Luengo. These partnerships enhance the research and development process, allowing for a more comprehensive approach to tackling complex medical challenges.

Conclusion

Jin Zeng's contributions to the field of pharmaceutical sciences are noteworthy, particularly in the area of KRAS modulation. His innovative patents and collaborative efforts are instrumental in advancing cancer treatment options. The impact of his work will likely resonate in the medical community for years to come.